Neuraltus Pharmaceuticals, Inc. reported disappointing results from its phase II clinical trial studying the impact of an immune regulator, NP001, in people living with ALS who had increased levels of inflammation. The company presented the negative results during the 70^th Annual American Academy of Neurology Meeting in Los Angeles.

Neuraltus had enrolled 138 individuals with ALS and systemic inflammation in a phase II study exploring whether NP001 slows the progression of ALS symptoms in people who have evidence of increased inflammatory activity in their blood. Inflammation is thought to be a contributing factor to ALS disease progression, and existing NP001 data suggested that it may have an effect on inflammation.

The trial did not meet its primary endpoint, a change from baseline in the ALS Functional Rating Scale-Revised (ALSFRS-R) or its secondary endpoint, a change in forced vital capacity, which measures pulmonary function.

Rich Casey, chief executive officer at Neuraltus, said that they are conducting additional analyses of the trial results to determine if and how they will proceed in developing NP001.

Read Neuraltus’ press release here.

For more information about the trial, click here.